← Leaderboards
Marianne D Sadar
British Columbia Cancer Agency
$5,847,836
Attributed
$5,847,836
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $718.6K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,847,836 · 2
By mechanism
R01$5,847,836 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Gene Expression”
- Jeffrey P Krischer · University Of South Florida$137,481,663
- Eric S Lander · Whitehead Institute For Biomedical Res$128,154,716
- Stacey Gabriel · Massachusetts Institute Of Technology$86,302,566
- Bruce W Stillman · Cold Spring Harbor Laboratory$82,324,317
- Michael P Snyder · Yale University$75,701,723
- Ronald G Crystal · Weill Medical College Of Cornell Univ$74,774,977
Research focus
Gene ExpressionCastrationPreventProteinsIn VivoMalignant Neoplasm Of ProstateRefractoryProtein Protein InteractionN-TerminalTranscription FactorAndrogen ReceptorNew Therapeutic TargetAnalogLigand Binding DomainDrug DevelopmentResistanceClinical TrialsHormonalAndrogen AntagonistsSmall MoleculeAndrogensGenesGlobal ChangeBase
Grant awards (21)
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$445,892
R01 · FY2025 · CA · contact PI
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$423,596
R01 · FY2024 · CA · contact PI
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$436,974
R01 · FY2023 · CA · contact PI
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$433,461
R01 · FY2022 · CA · contact PI
Structure, function, and application of novel antagonists of the intrinsically disordered androgen receptor amino-terminal domain as imaging agents and therapeutics$442,720
R01 · FY2021 · CA · contact PI
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$275,849
R01 · FY2021 · CA · contact PI
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$275,849
R01 · FY2020 · CA · contact PI
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$267,573
R01 · FY2019 · CA · contact PI
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$264,811
R01 · FY2018 · CA · contact PI
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$1
R01 · FY2018 · CA · contact PI
Delineating the mechanisms of androgen receptor activation function-1 antagonists for development of novel prostate cancer therapeutics$260,847
R01 · FY2017 · CA · contact PI
Novel compounds that inhibit transactivation of N-terminal domain of the androgen$265,355
R01 · FY2014 · CA · contact PI
Novel compounds that inhibit transactivation of N-terminal domain of the androgen$257,145
R01 · FY2013 · CA · contact PI
Novel compounds that inhibit transactivation of N-terminal domain of the androgen$248,081
R01 · FY2012 · CA · contact PI
Novel compounds that inhibit transactivation of N-terminal domain of the androgen$248,086
R01 · FY2011 · CA · contact PI
Novel compounds that inhibit transactivation of N-terminal domain of the androgen$222,742
R01 · FY2010 · CA · contact PI
Genomic and proteomic analysis of prostate cancer$209,928
R01 · FY2008 · CA · contact PI
Genomic and proteomic analysis of prostate cancer$209,928
R01 · FY2007 · CA · contact PI
Genomic and proteomic analysis of prostate cancer$216,198
R01 · FY2006 · CA · contact PI
Genomic and proteomic analysis of prostate cancer$221,400
R01 · FY2005 · CA
Genomic and proteomic analysis of prostate cancer$221,400
R01 · FY2004 · CA